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Abstract
Background: As abnormal growth might be the first manifestation of undetected diseases, it is important
to have accurate referral criteria and a proper diagnostic work-up. In the present paper we evaluate the
diagnostic work-up in secondary health care according to existing consensus guidelines and study the
frequency of underlying medical disorders.
Methods: Data on growth and additional diagnostic procedures were collected from medical records of
new patients referred for short stature to the outpatient clinics of the general paediatric departments of
two hospitals (Erasmus MC – Sophia Children's Hospital, Rotterdam and Spaarne Hospital, Haarlem)
between January 1998 and December 2002. As the Dutch Consensus Guideline (DCG) is the only
guideline addressing referral criteria as well as diagnostic work-up, the analyses were based on its seven
auxological referral criteria to determine the characteristics of children who are incorrectly referred and
the adequacy of workup of those who are referred.
Results: Twenty four percent of children older than 3 years were inappropriately referred (NCR). Of the
correctly referred children 74–88% were short corrected for parental height, 40–61% had a height SDS
<-2.5 and 21% showed height deflection (Δ HSDS < -0.25/yr or Δ HSDS < -1). In none of the children a
complete detailed routine diagnostic work up was performed and in more than 30% no routine laboratory
examination was done at all. Pathologic causes of short stature were found in 27 children (5%).
Conclusion:  Existing guidelines for workup of children with suspected growth failure are poorly
implemented. Although poorly implemented the DCG detects at least 5% pathologic causes of growth
failure in children referred for short stature. New guidelines for referral are required with a better
sensitivity and specificity, wherein distance to target height should get more attention. The general
diagnostic work up for short stature should include testing for celiac disease in all children and for Turner
syndrome in girls.
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Background
Short stature or a poor growth rate can be the first mani-
festation of undetected diseases in children. Poor growth
can be caused by a great diversity of congenital or acquired
conditions, such as Turner syndrome, growth hormone
deficiency (GHD) or celiac disease, for all of which early
diagnosis and treatment are important. When treated at
an early stage the effect on adult height is optimal and the
quality of life will presumably improve. The possibility for
proper treatment depends both on the early identification
of these children in the community and on the accurate
diagnostic work-up in the hospital afterwards.
For an early identification of children with abnormal
growth it is important to have accurate and well-defined
referral criteria, in combination with a good growth mon-
itoring system. In a previous study we performed an
inquiry about advised referral criteria among pediatric
endocrinologists in Europe as well as in most industrial-
ized countries around the world [1]. We concluded that
there was little consensus. Moreover the literature pro-
vides only few guidelines for the analysis of short stature
and these are based on consensus meetings rather than on
experimental evidence [2,3]. In experimental studies on
growth monitoring various arbitrary referral criteria were
used [4-6].
There is not only scarce evidence on referral criteria, but
also on the diagnostic work-up in secondary health care
for children with poor growth. Although there are a
number of consensus guidelines on the diagnosis of GHD
[7-11] and some articles on the analysis of short stature in
general [12-19], the articles are primarily expert-based
reviews on how to deal with short stature rather than
experimental studies on the outcome of laboratory inves-
tigations. Only one study evaluated the outcome of the
analysis of short stature in a growth clinic, but in this
study no standard protocol for the diagnostic work-up
was used [20]. The only guideline reported so far that
addresses the diagnostic work-up for short stature is the
Dutch Consensus Guideline (DCG) [3].
The DCG was prepared in 1996, containing a section on
referral criteria and a section on diagnostic procedures. Its
implementation consisted of a single publication in a
Dutch medical journal, a book and a couple of courses
[3,21]. It is not known how many doctors are aware of the
guideline and whether or not it changed medical prac-
tices.
In the present paper we wished to assess how many chil-
dren were correctly referred to secondary health care
according to the DCG, to evaluate the diagnostic work-up
in secondary health care and to study the frequency of
underlying medical disorders.
Methods
We performed a retrospective observational study in the
outpatient clinics of the general paediatric departments of
both a university hospital (Erasmus MC – Sophia Chil-
dren's Hospital, Rotterdam) and a general hospital
(Spaarne Hospital, Haarlem). In both clinics the DCG was
well known and used during the study period. All new
patients referred for short stature between January 1998
and December 2002 were identified retrospectively. The
children in whom the cause of growth retardation was
already known were excluded. A previously described
problem-orientated patient classification system [22] was
used to identify the children in the university hospital. In
the general hospital the children were identified by a local
registration system, consisting of a hand written registry of
reasons for referral of all new patients.
The following information was obtained from the medi-
cal records: date of birth, date of first presentation at the
outpatient clinic, gender, ethnicity, perinatal information
(birth weight, length, gestation, maternal obstetric prob-
lems etc.), family history, clinical presentation (symp-
toms and signs), information on puberty, longitudinal
height measurements until the first presentation at the
outpatient clinic, laboratory test results, radiological and
pathological evaluations and final diagnosis. If the ethnic-
ity was not recorded, it was assessed based on the patient's
first and family name according to an algorithm reported
earlier [23].
The DCG addresses five stages in the analysis of short stat-
ure. First of all it focuses on seven auxological referral cri-
teria (Table 1). When a child is referred according to these
criteria, the paediatrician is subsequently advised to fol-
low four diagnostic steps:
￿ The patient's history, the physical examination, growth
data and a hand radiograph should be collected to deter-
mine signs or symptoms that may indicate a specific dis-
ease.
￿ In the presence of specific clinical clues, appropriate fur-
ther specific investigations are done. When there are no
signs or symptoms leading to the suspicion of a certain
disease, a list of laboratory investigations is advised for
screening of several pathological conditions (Table 2).
￿ Dependent on the abnormalities in the screening labo-
ratory investigations further, more specific tests can be
performed to establish the final diagnosis.
￿ If there is no indication of a certain disease after the pre-
ceding procedures the three following tests should still be
considered: chromosomal analysis for Turner syndrome
in girls, a biopsy to prove or rule out celiac disease and theBMC Pediatrics 2008, 8:21 http://www.biomedcentral.com/1471-2431/8/21
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determination of zinc to investigate zinc deficiency in
children with failure to thrive [24].
For the evaluation of the diagnostic work up in this
project all stages were taken into account. The auxological
criteria as mentioned in the DCG were used to determine
whether the children were correctly referred to the outpa-
tient clinic. Since children under the age of three years
may not yet show a stable growth pattern but are still seek-
ing their individual growth channel (expressed as percen-
tile or standard deviation score (SDS) position), most
rules (1, 3–7) were not strictly applicable to this age
group. Therefore it was decided to analyse this group sep-
arately. For the analyses we allowed a child to meet several
criteria at the same time. Although plasma FSH in girls is
only of diagnostic value in girls younger than 2 and older
than 9 years, we analysed all ages in girls for this test, since
there is no such specific recommendation in the current
consensus.
All data were analysed in SPSS version 11. Height SDS was
calculated using the 1997 Dutch reference growth data
[25]. Small for gestational age (SGA) was defined as a
birth weight and/or length SDS < -2 for gestational age,
compared to recent Swedish reference values [26]. Differ-
ences between the two hospitals were calculated using the
chi-square test.
The study was approved by the Medical Ethical Commit-
tees of the Leiden University Medical Center, the Erasmus
Table 1: Seven auxological referral criteria taken from the Dutch Consensus Guideline [3].
Description rule Criteria Rule nr.
Absolute height HSDS* < -2.5 1
Clinical symptoms HSDS* < -1.3 AND (dysmorphic features OR disproportions) 2
Persistent short stature after 
born SGA**
SGA** AND HSDS* < -1.88 after the age of 2 years 3
Short for target height and 
population (HSDScorr)
: < 10 yr and > 13.4 yr; HSDS* < -1.3 AND HSDS-THSDS§ < -1.3 4
: < 9 yr and > 12.3 yr
Pubertal age‡:
: 10 – 13.4 yr;
: 9 – 12.3 yr
HSDS* < -1.3 AND HSDS-THSDS§ < -1.3 AND pubertal signs (: genit 
≥ Tanner stage 2 OR testis volume ≥ 4 ml; : breast ≥ Tanner stage 2)
5
Height deflection† : < 10 yr and > 13.4 yr; : < 
9 yr and > 12.3 yr
T2 – T1 > 1
(SDS1 – SDS2)/(T2-T1) < -0.25 OR (SDS1 – SDS2) < -1
6
Pubertal age‡:
: 10 – 13.4 yr; :
9 – 12.3 yr
T2 – T1 > 1
(SDS1 – SDS2)/(T2-T1) < -0.25 OR (SDS1 – SDS2) < -1 With pubertal 
signs
7
* HSDS = Height Standard Deviation Score (Height – mean height for the same age and sex/SD for the same age and sex)
**SGA = Small for gestational age
§ THSDS= Target Height Standard Deviation Score (Target height = (height of mother (+height of father +13) + 4.5)/2)
† Height deflection: Height deflection is formulated as Delta HSDS < -0.25 per year OR a delta HSDS <-1SDS over a longer period (not specified).
‡ Pubertal age: When a child does not show any pubertal signs (: genit ≥ Tanner stage 2 OR testis volume ≥ 4 ml; : breast >= Tanner stage 2) at 
this age referral is not necessary.
Table 2: Laboratory investigations in the diagnostic work up according the DCG
Laboratory investigations In order to diagnose Category
Blood
Hb, Ht, Leukocytes, Cell indices, Leukocyte differentiation, ESR (Ferritin) Anemia/infections (and celiac disease and cystic fibrosis) I
ALAT, ASAT, γ GT Liver diseases II
Albumin, Creatinine, Sodium, Potassium, Calcium, Phosphate, Alkaline 
phosphatase, acid-base equilibrium
Renal diseases III
IgA-anti endomysium, IgA- antigliadin, Anti-tissue glutaminase*, Total IgA Celiac disease IV
TSH, FT4 Hypothyroidism V
IGF-I Growth hormone deficiency VI
FSH** Turner syndrome VII
Urine
pH, glucose, protein, blood and sedimentation Renal diseases VIII
*At the moment the consensus meeting took place, anti tissue glutaminase as a diagnostic tool for celiac disease was not yet introduced nation 
wide.
**Only in girls.BMC Pediatrics 2008, 8:21 http://www.biomedcentral.com/1471-2431/8/21
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MC – Sophia Children's Hospital, Rotterdam and the
Spaarne Hospital, Haarlem.
Results
Patients
Between January 1998 and December 2002, 742 children
were referred to the two hospitals for short stature (univer-
sity hospital: n = 467, general hospital: n = 275) (see Fig.
1). Two hundred children were excluded either because
the cause of growth retardation was already known before
referral, the medical records were missing or there was
another reason for referral than short stature. Hence, 542
cases were suitable for analysis. Fifty-nine children were
under the age of 3 years at time of referral and were ana-
lysed separately. According to referral criteria mentioned
in the DCG 76.4% (77.1% in the university and 73.9% in
the general hospital) of the children older than 3 years
were correctly referred (CR). In 5.6% children (5.7% in
the university and 5.2% in the general hospital) there was
insufficient information to assess whether the referral met
the criteria (not classifiable (NC)) and in 18.0% the chil-
dren did not meet the referral criteria (not correctly
referred, NCR) according to the DCG (17.1% in the uni-
versity and 20.9% in the general hospital).
Details of all patients are shown in Table 3. The study
groups were significantly different between the two hospi-
tals for gender, ethnicity, height SDS (HSDS) at time of
referral and target height.
Referral criteria
Table 4 shows how many children in the correctly referred
group complied with the 7 different referral criteria men-
tioned in the DCG (although longitudinal data were used
for the analyses a child could only meet a specific referral
criterion once). There was a significant difference in refer-
Population description Figure 1
Population description.
=  
 BMC Pediatrics 2008, 8:21 http://www.biomedcentral.com/1471-2431/8/21
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ral pattern between the two hospitals with respect to abso-
lute height and "short for target height and population"
(HSDScorr). In both hospitals HSDScorr is the criterion
most complied with, followed by absolute height and
height deflection.
Diagnostic work-up after referral (Table 5)
In 43% of the correctly referred patients in the university
hospital and 32% in the general hospital, no routine lab-
oratory examination was done at all. In 52% and 49%,
respectively, only some of the categories mentioned in the
laboratory screening of the DCG were covered and in only
5% and 19% respectively, all categories were covered. In
none of the children a complete detailed routine diagnos-
tic work up was performed. There was a significantly dif-
ferent approach towards the diagnostic workup between
the two hospitals. In the general hospital more tests were
performed, with less distinction between the correctly
referred group and the non-correctly referred group. This
difference was significant for all categories in the routine
laboratory investigations except for the investigations for
renal diseases in blood and screening for Turner syn-
drome. Significantly more biopsies to rule out celiac dis-
ease and other, more specific tests were done in the
regional hospital. Less than a quarter of the girls were
screened on FSH for Turner syndrome in the correctly
referred group and in approximately 26% chromosomal
analysis for Turner syndrome was performed. When the
age rules recommended by paediatric endocrinologists
(plasma FSH only < 2 years and > 9 years, see material and
methods) were applied the figures hardly changed. The
determination of zinc was used only once in the diagnos-
tic work up.
Table 3: General characteristics of the study population in the university hospital (n = 398) and the general hospital (n = 144)
University hospital General hospital Difference between 2 hospitals (p-value)
Gender Male: n (%) 219 (55%) 65 (45%) 0.04
Ethnicity N (%)
Dutch/European 291 (73.1%) 127 (88.2%) 0.01
Turkish 31 (7.8%) 6 (4.2%)
Moroccan 11 (2.8%) 1 (0.7%)
Others: 54 (13.6%) 10 (6.9%)
Unknown 11 (2.8%) 0 (0%)
Age at time of referral (yrs): mean (SD) 9.1 (4.0) 8.4 (4.7) 0.2
HSDS at time of referral: mean (SD) -2.3 (0.8) -1.9 (0.9) < 0.01
THSDS: mean (SD) -0.7 (1.0) -0.2 (0.9) < 0.01
HSDS – THSDS at time of referral: mean (SD) -1.6 (0.8) -1.7 (1.0) 0.7
Delta HSDS in last year before referral: mean (SD) -0.08 (0.3) -0.10 (0.3) 0.5
Dysmorphic features: n (%) 22 (5.5%) 2 (1.4%) 0.1
Disproportion: n (%) 15 (3.8%) 2 (1.4%) 0.08
HSDS = height standard deviation score; THSDS = target height standard deviation score
Table 4: Auxological criteria applicable to the correctly referred (CR) group of children > 3 years old in both the university hospital (n 
= 284) and the general hospital (n = 85) (multiple criteria per patient are possible).
Description rule Rule nr. University hospital General hospital Difference between 2 
hospitals (p-value)
n (%) n (%)
Absolute height 1. 173 (60.9) 34 (40.0) 0.01
Clinical symptoms 2. 23 (8.1) 3 (3.5) 0.1
Persistent short stature after 
born SGA
3. 55 (19.4) 13 (15.3) 0.3
Short for target height and 
population (HSDScorr)
: < 10 yr and > 13.4 yr;
: < 9 yr and > 12.3 yr
4. 210 (73.9) 75 (88.2) 0.04
: 10 – 13.4 yr;
: 9 – 12.3 yr
5. 9 (3.2) 0 (0)
Height deflection : < 10 yr and > 13.4 yr;
: < 9 yr and > 12.3 yr
6. 58 (20.4) 18 (21.1) 0.9
: 10 – 13.4 yr;
: 9 – 12.3 yr
7.0  ( 0 ) 0  ( 0 )BMC Pediatrics 2008, 8:21 http://www.biomedcentral.com/1471-2431/8/21
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Outcome
In 80 children (14.8%) the diagnosis of persistent short
stature after born SGA could be made on the basis of
recorded birth size, although only 17 children (3.3%)
were classified as such by the physicians. Pathologic
causes of short stature were found in 27 children (5%)
(see Table 6). A large share of these were due to Turner,
GHD, and celiac disease. Other pathological causes were:
syndromes (n = 2: Noonan syndrome, Leri Weill syn-
drome), anaemia (n = 3), skeletal diseases (n = 4) and
emotional deprivation (n = 1). Three children born SGA
had also a pathologic cause for short stature (celiac dis-
ease, Turner syndrome and GHD). These three were clas-
sified under their pathologic cause and not under SGA in
Table 6.
Of all 27 children with pathologic outcome, seven were
referred for other reasons (anaemia (2), coughing (2),
delayed closure of fontanel (1), health check after adop-
tion (1), poor weight gain (1) and poor food intake (1))
in addition to their short stature. Five children had dys-
morphic features at the time of referral (2 children with
Turner syndrome, 1 child with Noonan, 1 child with
achondroplasia and 1 child with partial GHD) and 3 chil-
dren were disproportionate (2 children with achondro-
plasia and 1 child with Leri- Weill syndrome). Six children
had already been seen by a specialist before referral: 2 for
short stature (they were referred for a second opinion), 1
for hydrocephalus, 1 for exostoses, 1 for neurofibromato-
sis and glioma of the medulla oblongata and 1 for ASD,
but none of the children were previously investigated for
short stature. For none of the children the family or med-
ical history was helpful in determining the cause. Most of
the correctly referred children with pathology complied
with a deviant HSDScorr (83.4%), followed by absolute
height (see Table 7). The only child with a pathologic
cause that was incorrectly referred, had a height SDS of -
1.7 SDS at time of referral and was referred because of its
short stature in combination with an undefined anaemia.
The child turned out to have a beta-thalassemia.
Discussion
This study was designed to evaluate consensus guidelines
on poor growth in secondary health care and their out-
come in terms of pathology. According to the referral cri-
teria mentioned in the DCG 76.4% (284 in the university
and 85 in the general hospital) of the children older than
3 years were correctly referred. In both hospitals "short for
target height and population (HSDScorr)" appears to be
the criterion most complied with, followed by absolute
height and height deflection. The approach towards the
diagnostic workup was significantly different between the
two hospitals, but in none of the children a complete
detailed routine diagnostic work up was performed. Path-
ologic causes for short stature were found in 27 children
Table 5: Diagnostic work up in correctly (CR) and not correctly referred (NCR) children > 3 years old.
University hospital General hospital Difference in categories 
between 2 hospitals (p-value)
CR (n = 284) (%) NCR (n = 63) (%) CR (n = 85) (%) NCR (n = 24) (%)
Routine laboratory 
investigations
Anemia/infections 0.4/39.8 0.0/25.4 1.2/57.6 4.2/37.5 < 0.01
Liver diseases 22.5/4.2 2.8/0.0 14.1/21.2 8.3/25.0 0.03
Renal diseases (blood) 1.4/27.3 0.0/17.5 0.0/38.8 0.0/33.3 0.5
Celiac disease 21.1/15.8 11.1/3.2 49.4/4.7 25.0/4.2 < 0.01
Hypothyroidism 37.0/3.2 2.5/0.0 45.9/3.5 29.2/8.3 0.02
Growth hormone 
deficiency
35.2 9.5 45.9 25 0.02
Turner syndrome * 17.2 6.5 14.0 18.1 1.0
Renal diseases (urine) 0.0/19.4 0.0/19.0 0.0/40.0 0.0/29.2 < 0.01
Combined categories (at 
least one test category)
4.9/52.1 1.6/39.7 18.8/49.4 33.3/16.7 < 0.01
Further and specific 
diagnostics
Special investigations Chromosomal analyses 
for Turner syndrome*
26.2 6.5 26.0 0.0 0.9
Biopsy** 2.1 0.0 5.9 0.0 0.03
Zinc-determination 0.4 0.0 0.0 0.0 0.6
Further, more specific tests GH-tests 16.2 3.2 12.9 0.0 0.3
Other tests*** 8.8 3.2 28.2 25.0 < 0.01
Percentages of patients with Complete (all elements)/partial (at least one element) evaluation are given (several test categories per patient).
CR = Correctly referred; NCR = Not correctly referred
* These categories are only applicable to girls. The percentages are therefore calculated only on the female population.
**biopsy to rule out celiac disease.
*** other tests, like stool examinations, X-rays of the skeleton, ultrasounds of abdomen, hart, kidneys and thyroids, serum levels of steroids, genetic analyses, immunologic tests 
and allergic testsBMC Pediatrics 2008, 8:21 http://www.biomedcentral.com/1471-2431/8/21
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(5%) and in 80 children (14.8%) the short stature was
classified as persistent short stature after born SGA.
The Netherlands has a health care system based on refer-
ral, in which outpatient clinics of general paediatric
departments mainly provide secondary health care to
referred patients from the well organised national primary
health care system. Consequently we believe that by iden-
tifying all children referred for short stature to outpatient
clinics most children with short stature from the two geo-
graphical areas were gathered. The majority of the chil-
dren older than 3 years were referred correctly according
to the DCG. However, if the DCG had been followed
strictly, more than 38% of the normal population of chil-
dren would have been referred, as van Buuren et al
pointed out in their study [27].
The 5% of pathology found in our study concurs with pre-
vious reports [4,6,28]. In the Wessex growth study 8 chil-
dren (4.4%) were identified as having an organic disease
among the 180 children, whose height on screening at
school entry was below the 3rd  percentile [6]. In the
Oxford study Ahmed et al reported 7 newly recognized
children (3.0%) with organic disease among the 260 chil-
dren whose height was below – 2 SDS, measured at the
ages of 3 and 4.5 years [4]. In the Utah growth study [29]
twenty-five out of 555 children (4.5%) were newly discov-
ered as having GHD, hypothyroidism or Turner syndrome
and another 53 children (9.5%) had other medical rea-
sons for their poor growth (height below the 3rd percentile
and/or growth rate below 5 cm/yr). In contrast to these
population based studies Grimberg et al and Green et al
found a higher percentage of newly diagnosed children
with organic causes for their poor growth (23.7% (66 out
of 278 children and 40% (79 out of 198), respectively)
[20,29]. The children included in these studies were how-
ever referred to specialised growth centres because of short
Table 6: Diagnoses after diagnostic workup of short stature.
University hospital General hospital Total
Children < 3 years Children > 3 years Children < 3 years Children > 3 years
CR NCR NC CR NCR NC
n = 30 n = 284 n = 63 n = 21 n = 29 n = 85 n = 24 n = 6
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n = 542 (%)
G H D 1 6 000 000 7
C D 0 1 003 201 7
T u r n e r 0 2 000 100 3
O t h e r  p a t h o l o g y 4 5 100 000 1 0
Total pathology 5 (16.7) 14 (5.2) 1 (5.7) 0 (0) 3 (10.3) 3 (3.4) 0 (0.0) 1 (16.7) 27 (5.0)
SGA only 4 (13.3) 54 (20.1) 3 (3.5) 4 (18.2) 1 (3.4) 13 (14.9) 0 (0.0) 1 (16.7) 80 (14.8)
Idiopathic 21 (70) 216 (74.7) 59 (90.8) 17 (81.8) 25 (86.2) 69 (81.6) 24 (92.1) 4 (66.8) 435 (80.2)
CR = Correctly referred; NCR = Not correctly referred; NC = Not classifiable (information to confirm CR was lacking);
SGA = Small for gestational age (with persistent short stature after two years); GHD = Growth hormone deficiency; CD = Celiac disease
Table 7: Auxological criteria applicable to children with pathology < 3 yrs (n = 8, excluding SGA only) and correctly referred (CR) 
children with pathology > 3 yrs (n = 17, excluding SGA only) (multiple criteria per patient are possible).
Description rule Rule nr. < 3 yrs n (%) > 3 yrs n (%)
Absolute height 1. 7 (87.5) 11 (64.7)
Clinical symptoms 2. 2 (25.0) 5 (29.4)
Persistent short stature after born SGA 3. 0 (0.0) 3 (17.6)
Short for target height and population (HSDScorr) : < 10 yr and > 13.4 yr;
: < 9 yr and > 12.3 yr
4. 6 (75.0) 15 (88.2)
: 10 – 13.4 yr;
: 9 – 12.3 yr
5.
Height deflection : < 10 yr and > 13.4 yr;
: < 9 yr and > 12.3 yr
6. 2 (25.0) 3 (17.6)
: 10 – 13.4 yr;
: 9 – 12.3 yr
7.BMC Pediatrics 2008, 8:21 http://www.biomedcentral.com/1471-2431/8/21
Page 8 of 9
(page number not for citation purposes)
stature, without specific choices of anthropometric indica-
tors or criteria for abnormality.
In both hospitals most children with pathology older
than three years complied with the HSDScorr rule, fol-
lowed by the absolute height rule and height deflection
rule. This result is contrary to most findings in literature,
where absolute height is referred to as the most important
criterion for abnormal growth [1,2]. It concurs however
with the observation by Van Buuren et al that the best
decision rule to detect children with Turner syndrome,
one of the major causes of short stature, is the distance
between height SDS and target height [30]. In the 8 chil-
dren with pathology referred before the age of 3 years (CD
(n = 3), GHD (n = 1), anaemia (n = 2), skeletal diseases (n
= 2) and emotional deprivation (n = 1)) both HSDScorr
and absolute height seemed important criteria. According
to the English consensus these children would however
not have been diagnosed at this point, as it recommends
a single measurement at the age of 5 years old [2]. As these
children did not reach the age of 5 years in our study we
are not able to evaluate whether they would have been
picked up in the English system, but we can surely say that
there would have been a delay. Especially in the children
with GHD and celiac disease early diagnosis and treat-
ment is important for its prognosis. In order to improve
the referral criteria for growth monitoring with optimal
cut-off points, we believe that more studies, similar to the
recent report on Turner syndrome are required, with spe-
cific attention for children under the age of 3 years.
As far as we know, the DCG is the only published guide-
line on the general diagnostic work-up for short stature in
secondary health care. Despite the fact that this consensus
was well known in both hospitals participating in this
study, in none of the children a complete detailed routine
diagnostic work up as proposed in the DCG was per-
formed and in 43% of the patients in the university hos-
pital and 32% in the general hospital no routine
laboratory examination was done at all. The heterogeneity
of tests used in the diagnostic work up, resulting in many
missing data for the individual tests in this study, does
unfortunately not allow us to construct an evidence-based
decision rule for the general diagnostic work-up in chil-
dren with short stature. We know however from a previ-
ous study that testing on celiac disease should be part of
this work up, especially when there is no specific indica-
tion of another cause for short stature [31]. Likewise the
diagnosis of Turner syndrome should be considered in
any girl with unexplained short stature [32,33]. In con-
trast, the prior-probability of CF in infants or children
with a low weight or length for age is very low and there-
fore a sweat test is not necessary in all children with short
stature (Van Dommelen et al, submitted). Whether an
acid-base equilibrium is necessary in every child with
short stature to rule out renal acidosis will be addressed in
a later study. In the meantime, the available evidence so
far can be used to construct a new guideline with an
expected acceptable efficacy and efficiency.
Conclusion
For the identification of children with abnormal growth
accurate and well-defined referral criteria and a diagnostic
work up are important. The current study shows that with
the DCG, though only partially adhered to, at least 5%
pathologic growth failure could be detected. In a substan-
tial part of these children (30%) there would at least have
been a delay in diagnosis if the English consensus guide-
line would have been used. From previous studies it is
known on the other hand that the DCG leads to too many
referrals [27]. Therefore new guidelines are needed with a
better sensitivity and specificity, in which target height
should play a more prominent role. We have recently pro-
posed such guidelines [34]. Furthermore, the implemen-
tation process should receive more attention Concerning
the general diagnostic work up for short stature we
emphasise the importance of testing for celiac disease in
all children and for Turner syndrome in girls.
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